File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3109/03009749309099251
- Scopus: eid_2-s2.0-0027276083
- PMID: 8316776
- WOS: WOS:A1993LJ69900001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis
Title | Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis |
---|---|
Authors | |
Keywords | Platelet activation Vasospastic disease |
Issue Date | 1993 |
Publisher | Informa Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03009742.asp |
Citation | Scandinavian Journal Of Rheumatology, 1993, v. 22 n. 3, p. 97-101 How to Cite? |
Abstract | Platelet activation may have a pathophysiological role in Raynaud's phenomenon (RP). However, previous studies have shown conflicting results. This may be related to patient selection and the choice of platelet function assay. In this study, we have assessed platelet function of 30 patients with severe RP with (n = 14) or without (n = 16) systemic sclerosis (SSc), using a whole blood platelet aggregation (PA) assay. Raynaud's medication or other drugs which may affect PA were stopped at least 2 weeks previously. Spontaneous whole blood PA and that induced by 0.5 μM adenosine diphosphate and 0.6 and 1 μg/ml collagen were significantly increased in both groups of patients when compared with controls. There were no significant differences in PA between the 2 groups of patients. Using a more physiological assay, patients with severe RP, whether or not associated with SSc, were shown to have abnormally increased platelet activity. Hyperactive platelets may further impede blood flow in RP. |
Persistent Identifier | http://hdl.handle.net/10722/161978 |
ISSN | 2023 Impact Factor: 2.2 2023 SCImago Journal Rankings: 0.638 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lau, CS | en_US |
dc.contributor.author | Mclaren, M | en_US |
dc.contributor.author | Saniabadi, A | en_US |
dc.contributor.author | Belch, JJF | en_US |
dc.date.accessioned | 2012-09-05T05:16:26Z | - |
dc.date.available | 2012-09-05T05:16:26Z | - |
dc.date.issued | 1993 | en_US |
dc.identifier.citation | Scandinavian Journal Of Rheumatology, 1993, v. 22 n. 3, p. 97-101 | en_US |
dc.identifier.issn | 0300-9742 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/161978 | - |
dc.description.abstract | Platelet activation may have a pathophysiological role in Raynaud's phenomenon (RP). However, previous studies have shown conflicting results. This may be related to patient selection and the choice of platelet function assay. In this study, we have assessed platelet function of 30 patients with severe RP with (n = 14) or without (n = 16) systemic sclerosis (SSc), using a whole blood platelet aggregation (PA) assay. Raynaud's medication or other drugs which may affect PA were stopped at least 2 weeks previously. Spontaneous whole blood PA and that induced by 0.5 μM adenosine diphosphate and 0.6 and 1 μg/ml collagen were significantly increased in both groups of patients when compared with controls. There were no significant differences in PA between the 2 groups of patients. Using a more physiological assay, patients with severe RP, whether or not associated with SSc, were shown to have abnormally increased platelet activity. Hyperactive platelets may further impede blood flow in RP. | en_US |
dc.language | eng | en_US |
dc.publisher | Informa Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03009742.asp | en_US |
dc.relation.ispartof | Scandinavian Journal of Rheumatology | en_US |
dc.subject | Platelet activation | - |
dc.subject | Vasospastic disease | - |
dc.subject.mesh | Adenosine Diphosphate - Pharmacology | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Collagen - Pharmacology | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Fibrinogen - Analysis | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Platelet Activation | en_US |
dc.subject.mesh | Platelet Aggregation - Drug Effects | en_US |
dc.subject.mesh | Platelet Count | en_US |
dc.subject.mesh | Raynaud Disease - Physiopathology | en_US |
dc.subject.mesh | Scleroderma, Systemic - Complications - Physiopathology | en_US |
dc.title | Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lau, CS:cslau@hku.hk | en_US |
dc.identifier.authority | Lau, CS=rp01348 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.3109/03009749309099251 | - |
dc.identifier.pmid | 8316776 | - |
dc.identifier.scopus | eid_2-s2.0-0027276083 | en_US |
dc.identifier.volume | 22 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 97 | en_US |
dc.identifier.epage | 101 | en_US |
dc.identifier.isi | WOS:A1993LJ69900001 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Lau, CS=14035682100 | en_US |
dc.identifier.scopusauthorid | McLaren, M=7005471705 | en_US |
dc.identifier.scopusauthorid | Saniabadi, A=18936909200 | en_US |
dc.identifier.scopusauthorid | Belch, JJF=7101752870 | en_US |
dc.identifier.issnl | 0300-9742 | - |